Rafferty Asset Management
ADMA icon

Rafferty Asset Management’s ADMA Biologics ADMA Stock Holding History

Rafferty Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81M Sell
215,996
-45,704
-17% -$417K ﹤0.01% 664
2026
Q1 		$2.36M Sell
261,700
-29,461
-10% -$465K 0.01% 573
2025
Q4 		$5.31M Sell
291,161
-64,990
-18% -$1.1M 0.02% 418
2025
Q3 		$5.22M Buy
356,151
+90,223
+34% +$1.55M 0.02% 415
2025
Q2 		$4.84M Buy
265,928
+42,590
+19% +$868K 0.02% 407
2025
Q1 		$4.43M Sell
223,338
-289,790
-56% -$5.01M 0.02% 396
2024
Q4 		$8.8M Buy
513,128
+122,173
+31% +$2.3M 0.03% 306
2024
Q3 		$7.82M Buy
390,955
+111,078
+40% +$1.73M 0.03% 323
2024
Q2 		$3.13M Sell
279,877
-402,388
-59% -$3.38M 0.01% 518
2024
Q1 		$4.5M Buy
682,265
+137,916
+25% +$754K 0.02% 494
2023
Q4 		$2.46M Sell
544,349
-81,147
-13% -$300K 0.01% 624
2023
Q3 		$2.24M Sell
625,496
-92,632
-13% -$357K 0.01% 577
2023
Q2 		$2.65M Sell
718,128
-263,103
-27% -$975K 0.01% 567
2023
Q1 		$3.25M Buy
981,231
+191,833
+24% +$663K 0.02% 492
2022
Q4 		$3.06M Buy
789,398
+209,548
+36% +$646K 0.03% 478
2022
Q3 		$1.41M Buy
+579,850
New +$1.39M 0.02% 588

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management's ADMA Position: Q2 2026 in Review

Rafferty Asset Management reduced its ADMA Biologics (ADMA) stake by 17% in Q2 2026, selling an estimated $417K and leaving 215,996 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #664.

Rafferty Asset Management first reported a position in ADMA in Q3 2022 and has held it in 16 quarters since. The position peaked at $8.8M in Q4 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Rafferty Asset Management held 215,996 shares of ADMA Biologics worth $1.81M as of Q2 2026.
  • Rafferty Asset Management sold 45,704 ADMA Biologics shares in Q2 2026, an estimated $417K.
  • ADMA Biologics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #664 holding.
  • Rafferty Asset Management first reported a position in ADMA Biologics in Q3 2022 and has held it in 16 quarters since.
  • Rafferty Asset Management's ADMA Biologics position peaked at $8.8M in Q4 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.